#1 Clinical Trials Search in Europe

Dazukibart

Dazukibart is an innovative drug being studied for the treatment of idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM). These conditions cause muscle inflammation and weakness, significantly impacting patients’ quality of life. This article explores the ongoing clinical trials of Dazukibart, its potential benefits, and what patients can expect from this new treatment option.

Table of Contents

What is Dazukibart?

Dazukibart is a new investigational medicine that is being studied for the treatment of idiopathic inflammatory myopathies. It is classified as an anti-interferon beta therapy, which means it targets a specific part of the immune system involved in these conditions.[1]

What Conditions Does Dazukibart Treat?

Dazukibart is being studied specifically for two types of idiopathic inflammatory myopathies:

  • Dermatomyositis (DM): A condition that causes muscle weakness and a characteristic skin rash.
  • Polymyositis (PM): A condition that causes muscle weakness without the skin involvement seen in dermatomyositis.

Both of these conditions are part of a group of disorders that cause inflammation in the muscles used for movement. They primarily affect the muscles closest to the center of the body, such as those in the hips, thighs, upper arms, and neck.[1]

How Does Dazukibart Work?

While the exact mechanism is not fully detailed in the provided information, Dazukibart is described as an anti-interferon beta therapy. This suggests that it works by targeting and suppressing the activity of interferon beta, a protein involved in immune system responses. In conditions like dermatomyositis and polymyositis, the immune system is overactive, causing inflammation and damage to muscles. By modulating the immune response, Dazukibart may help reduce this inflammation and improve symptoms.[1]

How is Dazukibart Administered?

Dazukibart is administered as an intravenous (IV) infusion. This means the medicine is given directly into the veins. The infusion takes about 1 hour and is given every 4 weeks. In the current study, participants receive the treatment from Day 1 to Week 48 (about 12 months).[1]

Details of the Clinical Study

The current study for Dazukibart is a Phase 3, multi-center, open-label extension study. This means:

  • It’s in an advanced stage of clinical testing (Phase 3)
  • It’s being conducted at multiple research centers
  • All participants know they are receiving the study drug (open-label)
  • It’s an extension of a previous study, allowing researchers to gather long-term data

The study aims to investigate the long-term safety, tolerability, and efficacy of Dazukibart in people with active idiopathic inflammatory myopathies. Participants in this study have previously taken part in a study of Dazukibart for dermatomyositis or polymyositis.[1]

Primary Outcomes Being Studied

The main outcomes that researchers are looking at include:

  1. Safety and side effects: This includes monitoring for any adverse events, especially those that are serious or lead to discontinuation of treatment.[1]
  2. Laboratory abnormalities: Checking for any significant changes in blood tests or other lab results.[1]
  3. Vital sign changes: Monitoring for any significant changes in heart rate or blood pressure.[1]
  4. ECG abnormalities: Looking for any changes in heart rhythm, especially something called QTc prolongation.[1]
  5. Lung function: Measuring changes in lung capacity and the ability of the lungs to transfer oxygen.[1]
  6. Mental health: Assessing for any signs of suicidal thoughts or behaviors.[1]

Secondary Outcomes Being Studied

Additional outcomes being measured include:

  • Changes in muscle strength
  • Overall disease activity as assessed by doctors and patients
  • Improvements in skin symptoms for those with dermatomyositis
  • Changes in physical function and quality of life
  • Changes in fatigue levels
  • Changes in medication use, including the ability to reduce other treatments
  • Healthcare resource utilization

These outcomes are measured using various standardized scales and questionnaires.[1]

Potential Benefits of Dazukibart

While the full results of the study are not yet known, the potential benefits of Dazukibart for people with dermatomyositis or polymyositis may include:

  • Improved muscle strength and function
  • Reduction in overall disease activity
  • Improvement in skin symptoms for those with dermatomyositis
  • Better quality of life and physical function
  • Reduced fatigue
  • Possibility of reducing or stopping other medications

It’s important to note that as this is an ongoing study, the full benefits and potential risks of Dazukibart are still being evaluated.[1]

Aspect Details
Drug Name Dazukibart
Drug Type Anti-interferon beta therapy
Conditions Studied Dermatomyositis (DM) and Polymyositis (PM)
Administration Method Intravenous (IV) infusion, 1 hour every 4 weeks
Study Duration 48 weeks of treatment + 4 months safety follow-up
Primary Outcomes Safety, tolerability, adverse events, laboratory abnormalities, vital signs, ECG changes, lung function
Secondary Outcomes Muscle strength, disease activity, skin symptoms (DM), quality of life, fatigue, healthcare utilization
Potential Benefits Improved muscle strength, reduced inflammation, better lung function, enhanced quality of life

FAQ

  • What is Dazukibart and how does it work? Dazukibart is an anti-interferon beta therapy being studied for the treatment of idiopathic inflammatory myopathies. It works by targeting specific inflammatory pathways in the body that are believed to contribute to muscle inflammation and weakness in conditions like dermatomyositis and polymyositis.
  • How is Dazukibart administered in the clinical trial? In the clinical trial, Dazukibart is given as an intravenous (IV) infusion directly into the veins. The infusion takes about 1 hour and is administered every 4 weeks for up to 48 weeks (about 12 months).
  • What are the main goals of the Dazukibart clinical trial? The main goals of the trial are to investigate the long-term safety, tolerability, and effectiveness of Dazukibart in people with idiopathic inflammatory myopathies. The study aims to understand how well the drug works and if it can improve muscle strength, skin symptoms, and overall quality of life for patients.
  • Who can participate in the Dazukibart clinical trial? The trial is seeking participants who have previously taken part in a dermatomyositis (DM) or polymyositis (PM) study involving Dazukibart. Some participants will receive the study medicine, while others will only complete safety follow-up without receiving the drug.
  • What are the potential benefits of Dazukibart for patients with DM or PM? Potential benefits of Dazukibart may include improved muscle strength, reduced inflammation, better lung function, and enhanced quality of life. The trial will measure various outcomes, including changes in muscle strength, skin symptoms in DM patients, and overall disease activity, to determine the drug's effectiveness.

Ongoing Clinical Trials on Dazukibart

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +4

Glossary

  • Idiopathic Inflammatory Myopathies: A group of disorders characterized by inflammation of the muscles used for movement, including dermatomyositis and polymyositis.
  • Dermatomyositis (DM): A type of idiopathic inflammatory myopathy that causes muscle weakness and skin rash.
  • Polymyositis (PM): A type of idiopathic inflammatory myopathy that causes muscle weakness without skin involvement.
  • Intravenous (IV) infusion: A method of administering medication directly into the veins using a needle or catheter.
  • Adverse Event (AE): Any undesirable medical occurrence in a participant who received study treatment, regardless of its potential relationship to the treatment.
  • Serious Adverse Event (SAE): An adverse event resulting in severe outcomes such as death, hospitalization, or significant disability.
  • Forced Vital Capacity (FVC): The volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
  • Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO): A measure of how well gases can pass from the lungs into the blood.
  • Manual Muscle Testing – 8 designated muscles (MMT-8): A test that measures the strength of 8 specific muscle groups, with scores ranging from 0 to 150 (higher scores indicate better muscle strength).
  • Physician Global Activity (PhGA): A measure of overall disease activity as assessed by a physician, using a 0 to 10 scale (higher scores indicate worse disease activity).
  • Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): A tool used to measure the extent and severity of skin involvement in dermatomyositis patients.
  • Patient-Reported Outcomes Measurement Information System – Physical Function (PROMIS-PF): A questionnaire that assesses a patient's physical function, with scores ranging from 0 to 100 (higher scores indicate better physical function).
  • Health Assessment Questionnaire-Disability Index (HAQ-DI): A questionnaire that measures a patient's ability to perform daily activities, with scores ranging from 0 to 3 (higher scores indicate worse disability).
  • Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F): A questionnaire that measures fatigue in patients with chronic illnesses, with scores ranging from 0 to 52 (higher scores indicate less fatigue).

References

  1. https://clinicaltrials.gov/study/NCT06698796